Business Wire

Q4 Announces Strategic Partnership with Rose & Company to Bring New Investor Access Solutions to Listed Companies

16.4.2020 17:30:00 EEST | Business Wire | Press release

Share

Q4 Inc. (Q4), a leading global provider of cloud-based investor relations solutions, and Rose & Company (Rose & Co), the industry’s premier strategic investor relations advisory firm, today announced an exclusive partnership that combines the deep capital markets experience and proven success of Rose & Co’s unique investor access service with Q4’s market-leading IR platform. Together, Q4 and Rose & Co will focus on helping public companies both target and directly engage with institutional investors through an ongoing sales and marketing process.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200416005578/en/

“We are excited to be partnering with Rose & Co, giving our clients the benefit of their extensive capital markets and sell-side experience ” said Darrell Heaps, CEO of Q4. “In a world where IR teams are tasked with doing more with less, this partnership provides significant strategic value and a competitive advantage for our clients through the technology and expertise needed to effectively target and directly engage high quality investors.”

“Q4 offers the best-in-class products and services for investor relations professionals, and we look forward to extending their ability to help listed companies engage with the most appropriate audience of institutional investors,” said Simon Rose, CEO of Rose & Co. “The partnership combines the strengths of two industry leaders to offer the only end-to-end solution for public companies to manage their IR workflow, target desirable shareholders and engage directly with the senior decision makers at institutional money managers around the world.”

The partnership between Q4 and Rose & Co was formed to address the need of public companies, to efficiently and directly engage with the buy-side. By combining thoughtful, proactive investor access with innovative technology, IR teams and executives will be better positioned to access high-quality institutional investors, and to foster productive ongoing relationships with current and prospective shareholders. Further collaboration between the partners will focus on public companies’ investor access needs and the products required to compete in the ever-changing capital markets.

About Q4 Inc.
Q4 is a leading global provider of cloud-based investor relations, with the mission of partnering with customers to achieve their strategic IR objectives. Through best-in-class customer experience and an innovative suite of IR technology, Q4 is a trusted partner to over 2,000 of the world’s largest brands. Q4’s comprehensive portfolio of IR communications and intelligence solutions, supported by an industry-leading customer experience model, empower customers to build impactful and strategic IR programs. Q4 has offices in New York, Toronto, Copenhagen, and London. To learn more, visit: www.q4inc.com.

About Rose & Company
Rose & Company is a strategic advisory firm dedicated to helping clients successfully navigate the global capital markets. We work with our clients to evaluate, define and execute strategies to enhance their presence in increasingly globalized and complex capital markets. For more information, please visit www.roseandco.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Julia Hanbury | Talk Shop | 604-738-2220 | julia@talkshopmedia.com

Robert Brinberg | Rose & Company | 212-257-5932 | robert@roseandco.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye